Bayer
BAYN.DEBAYN.DE · Stock Price
Historical price data
Overview
Bayer AG's mission is 'Health for all, Hunger for none,' focusing on advancing healthcare and food security through science-led innovation. The company has achieved significant scale and diversification, most notably through the transformative acquisition of Monsanto, establishing a leading position in agricultural sciences. Its strategy centers on driving growth in its core pharmaceutical pipeline—particularly in oncology, cardiology, and cell & gene therapy—while navigating legacy legal challenges and optimizing its portfolio to enhance shareholder value and operational focus.
Technology Platform
A multi-modal platform integrating precision medicine (small molecules & biologics), cell & gene therapy (iPSC and AAV platforms), and data science/AI across drug discovery, development, and digital health applications.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| E2 transdermal (Julina, BAY86-5435) | Osteoporosis, Postmenopausal | Pre-clinical | |
| Apalutamide + Darolutamide (BAY 1841788) + Enzalutamide | Non-metastatic Castration-resistant Prostate Cancer | Pre-clinical | |
| Doxorubicin + Cyclophosphamide + Paclitaxel + Sorafenib | Breast Cancer | Pre-clinical | |
| Radium-223 dichloride (Xofigo, BAY88-8223) | Castration-resistant Prostate Cancer | Pre-clinical | |
| Rivaroxaban (Xarelto,Bay 59-7939) + Acetylsalicylic acid(ASA... | Prevention of Atherothrombotic Events | Pre-clinical |
FDA Approved Drugs
50Opportunities
Risk Factors
Competitive Landscape
Bayer faces intense competition across all segments: in Pharmaceuticals from global pharma giants and biotechs (e.g., Pfizer, AstraZeneca, Johnson & Johnson); in Crop Science from integrated peers like Syngenta, BASF, and Corteva; and in Consumer Health from players like Johnson & Johnson, GSK, and Sanofi. Its integrated life sciences model is unique but under scrutiny for creating a conglomerate discount.